# EDGAR Filing Document

**Accession Number:** 0000896264
**File Stem:** 0000896264-26-000014
**Filing Date:** 2026-2
**Character Count:** 83316
**Document Hash:** 4bac8071996762bf89db73df3357f887
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000896264-26-000014.hdr.sgml**: 20260218

**ACCESSION NUMBER**: 0000896264-26-000014

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20260217

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260218

**DATE AS OF CHANGE**: 20260217

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** USANA HEALTH SCIENCES INC
- **CENTRAL INDEX KEY:** 0000896264
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870500306
- **STATE OF INCORPORATION:** UT
- **FISCAL YEAR END:** 0103

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35024
- **FILM NUMBER:** 26644868

**BUSINESS ADDRESS:**
- **STREET 1:** 3838 WEST PARKWAY BLVD.
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84120-6336
- **BUSINESS PHONE:** 8019547100

**MAIL ADDRESS:**
- **STREET 1:** 3838 WEST PARKWAY BLVD.
- **STREET 2:** 3838 WEST PARKWAY BLVD.
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84120-6336

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** USANA INC
- **DATE OF NAME CHANGE:** 19930125

?xml version='1.0' encoding='ASCII'? usna-20260217

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**_____________________**

**FORM 8-K**

**_____________________**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

February 17, 2026

**USANA HEALTH SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

Utah

(State or other jurisdiction of incorporation)

001-35024 87-0500306 <br> (Commission File No.) (IRS EmployerIdentification No.)

3838 West Parkway Boulevard

Salt Lake City**,** Utah 84120

(Address of principal executive offices, Zip Code)

Registrant's telephone number, including area code: (801) 954-7100

Check the appropriate box below if the Form 8-K ﬁling is intended to simultaneously satisfy the ﬁling obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.001 par value per share | USNA | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

**Item 2.02&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.**

On February 17, 2026, USANA Health Sciences, Inc. (the "Company" or "USANA") issued a press release announcing its financial results for the fourth quarter and fiscal year ended January 3, 2026. The release also announced that the Company will post a document titled "Management Commentary" on the Company's website and that executives of the Company will hold a conference call with investors, to be broadcast over the World Wide Web and by telephone and provided access information, date and time for the conference call. The Company noted that the call will consist of brief remarks by the Company's management team, before moving directly into questions and answers. A copy of the press release, and the Management Commentary, are furnished herewith as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. These documents will be posted on the Company's corporate website, www.usana.com.

The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report, including the exhibits, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.

**Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure**

The information disclosed above under Item 2.02, as well as the exhibits attached under Item 9.01 below are incorporated herein by reference.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Press release issued by USANA Health Sciences, Inc. dated](q42025earningsreleaseex991.htm)[February 17, 2026](q42025earningsreleaseex991.htm)[(furnished herewith).](q42025earningsreleaseex991.htm)</u> |
| 99.2 | <u>[Management Commentary provided by USANA Health Sciences, Inc. dated](q42025managementcommentary.htm)[February 1](q42025managementcommentary.htm)[7, 2026](q42025managementcommentary.htm)[(furnished herewith).](q42025managementcommentary.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **USANA HEALTH SCIENCES, INC.** | **USANA HEALTH SCIENCES, INC.** |
| | **By:** | /s/ G. Douglas Hekking |
| | G. Douglas Hekking, Chief Financial Officer | G. Douglas Hekking, Chief Financial Officer |
| Date: February 17, 2026 |  |  |

---

## Exhibit 99.1

![usanacorplogoresizedb.jpg](usanacorplogoresizedb.jpg)

**USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook**

**SALT LAKE CITY, February 17, 2026** (BUSINESS WIRE)—USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended January 3, 2026.

**Key Financial and Operating Results**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Q4 2025** | **Q4 2024** | **FY 2025** | **FY 2024** |
| Net sales | $226.2 | $213.6 | $925.3 | $854.5 |
| Net (loss) earnings\* | $-1.8 | $4.5 | $10.8 | $42.0 |
| Diluted EPS | $-0.10 | $0.23 | $0.58 | $2.19 |
| Adjusted diluted EPS<sup>(1)</sup> | $0.60 | $0.64 | $1.93 | $2.59 |
| Adjusted EBITDA<sup>(2)</sup> | $27.3 | $25.5 | $101.3 | $110.3 |
| USANA Active Customers | 387000 | 454000 | 387000 | 454000 |
| Hiya Active Monthly Subscribers | 181700 | N/A | 181700 | N/A |

---

*\*Pretax earnings for Q4 2025 totaled $4.0 million with income tax expense of $5.8 million. The adjustment to income taxes during the period, largely as a result of one-time impairment and cost realignment charges, is about $3.1 million greater than what would have been expected using the previously expected 65% tax rate.*

*Net sales, Net (loss) earnings and Adjusted EBITDA figures in millions.*

*Net earnings, EPS and Adjusted EBITDA figures represent amounts attributable to USANA.*

**Fiscal Year 2026 Outlook**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consolidated net sales between $925 million and $1.0 billion, or flat to 8% growth.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net earnings between $20.3 million and $26.6 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Diluted EPS between $1.11 and $1.45.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted Diluted EPS<sup>(1)</sup> between $1.95 and $2.29.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA<sup>(2)</sup> between $101.3 million and $109.3 million.

------

**Q4 2025 Financial Performance**

---

| | | | |
|:---|:---|:---|:---|
| **Consolidated Results** | **Consolidated Results** | **Consolidated Results** | **Consolidated Results** |
| | | **Year-Over-Year** | **Sequentially** |
| **Net sales** | $226 million | +6% \* | +6% \* |
| **Net (loss)** | -$1.8 million | N/A | N/A |
| **Diluted EPS** | -$0.10 | N/A | N/A |
| **Adjusted diluted EPS**<sup>(1)</sup> | $0.60 | -6% | N/A |
| **Adjusted EBITDA**<sup>(2)</sup> | $27.0 million | +7% | +98% |

---

*\*No meaningful FX impact*

*Net (loss) earnings, EPS and Adjusted EBITDA figures represent amounts attributable to USANA.*

"USANA delivered fourth quarter net sales in line with our preliminary results announced on January 12, 2026," said Kevin Guest, Chairman and Chief Executive Officer. "We began to see signs of stabilization in active customer counts in our core nutritional business as net sales in this segment increased modestly sequentially, led by growth in key markets including mainland China, the United States and Canada. Meanwhile, our omnichannel brands, Hiya and Rise, posted solid year-over-year growth."

**Fiscal Year 2025 Financial Performance**

---

| | | |
|:---|:---|:---|
| **Consolidated Results** | **Consolidated Results** | **Consolidated Results** |
| **Net sales** | $925 million | +8% YOY |
|  |  | +9% constant currency |
|  |  | -$3 million YOY FX impact |
| **Net earnings** | $10.8 million | -74% |
| **Diluted EPS** | $0.58 | -74% |
| **Adjusted diluted EPS**<sup>(1)</sup> | $1.93 | -25% |
| **Adjusted EBITDA**<sup>(2)</sup> | $101.3 million | -8% |

---

*Net earnings, EPS and Adjusted EBITDA figures represent amounts attributable to USANA*

Mr. Guest continued, "Fiscal 2025 net sales grew 8%, driven primarily by a full-year contribution from Hiya. Net sales in the core nutritional business declined 8%, reflecting a challenging environment for customer acquisition in key markets. Despite this challenge, we continued to execute our diversification strategy towards an omnichannel model. That strategy is designed to support growth beyond our core nutritional business as well as to restructure and modernize our business for today's evolving marketplace.

------

Rise Wellness generated strong momentum with sales tripling, albeit off a small base in 2024, as distribution expanded into key retail outlets. The business is on pace for a robust year of sales growth supported by the launch of Protein Pop at a large club retailer in the first quarter. Net sales outside of our core nutritional business represented 16% of consolidated net sales in 2025, up from approximately 1% in 2024. We expect this share to increase to more than 20% of consolidated net sales in fiscal 2026."

**Q4 2025 Core Nutritional Business Regional Results:**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Asia Pacific Region** | **Asia Pacific Region** | **Asia Pacific Region** | **Asia Pacific Region** | **Asia Pacific Region** |
| | | **Year-Over-Year** | **Year-over-Year (Constant Currency)** | **Sequentially** |
| **Net sales** | $151 million | -10% | No material FX impact | +8% |
| **USANA Active Customers** | 306000 | -15% | N/A | -1% |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** |
| | | | **Year-Over-Year** | **Year-over-Year (Constant Currency)** | **Sequentially** |
| **Greater China** | **Net sales** | $100 million | -11% | No material FX impact | +8% |
| **Greater China** | **USANA Active** | 208000 | -15% | N/A | -1% |
| **Greater China** | **Customers** | 208000 | -15% | N/A | -1% |
| **North Asia** | **Net sales** | $17 million | +2% | +5% | -5% |
| **North Asia** | **USANA Active** | 35000 | -8% | N/A | -5% |
| **North Asia** | **Customers** | 35000 | -8% | N/A | -5% |
| **Southeast Asia Pacific** | **Net sales** | $34 million | -10% | -12% | +17% |
| **Southeast Asia Pacific** | **USANA Active** | 63000 | -18% | N/A | +3% |
| **Southeast Asia Pacific** | **Customers** | 63000 | -18% | N/A | +3% |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Americas and Europe Region** | **Americas and Europe Region** | **Americas and Europe Region** | **Americas and Europe Region** | **Americas and Europe Region** |
| | | **Year-Over-Year** | **Year-over-Year (Constant Currency)** | **Sequentially** |
| **Net sales\*** | $45 million | +1% | Flat | +4% |
| **USANA Active Customers** | 81000 | -13% | N/A | +1% |

---

*\*Includes $4.5 million of 'Other'*

**Q4 2025 Hiya Direct to Consumer Results:**

---

| | |
|:---|:---|
| **Hiya** | **Hiya** |
| **Net sales** | $30 million |
| **Active Monthly Subscribers** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;181700 |

---

**Balance Sheet**

The Company ended the year with $158 million in cash and cash equivalents and $14 million of debt. As of January 3, 2026, inventory totaled $107 million, an increase of approximately $35 million, or 48% compared to balances at year-end 2024. This increase was primarily driven by the addition of inventory to support the rapid growth of the Rise Wellness brands and a planned ramp up of raw materials inventory as part of bringing the production of Hiya products in-house. Importantly, our balance sheet remains in a strong net cash position, providing us with the financial flexibility to continue executing our strategic priorities.

The Company repurchased 927,000 shares in fiscal 2025 for an investment of $28 million. As of January 3, 2026, the Company had approximately $34 million remaining under the current share repurchase authorization.

**Fiscal Year 2026 Outlook**

Mr. Guest continued, "We are leveraging our strong foundation in the nutrition business and expanding beyond our legacy channel to connect with a greater number of health-conscious consumers worldwide. We see an extraordinary opportunity in a growing global health and wellness market to strengthen our brand relevance through an omnichannel approach. By deepening consumer engagement, empowering our Brand

------

Partners, and executing with discipline, we believe we can accelerate profitable growth, extend our competitive advantages, and deliver sustainable long-term value for our shareholders.

"We also remain focused on product innovation and development to meet the evolving nutritional needs of our consumers. We introduced several new products and upgraded several top-selling products in 2025, and plan to launch these products across all markets in 2026. Furthermore, we intend to accelerate our technology initiatives to modernize our core systems and fundamentally improve how customers experience our brand while driving future cost efficiencies across our IT infrastructure. We are planning to strategically leverage best-in-class third-party platforms to move faster, scale smarter, and deliver capabilities to enable future growth and improve customer interactions. Our focus is on deploying the most effective technologies and partnering with industry-leading providers to create real value for customers and a durable advantage for our business. As I have recently resumed the CEO role, this plan is still being finalized and is not reflected in our fiscal 2026 guidance, and we will provide an update upon its full formalization and approval.

"Hiya is expected to deliver solid top line growth in 2026, driven by continued strength in its core direct-to-consumer business and early expansion into new distribution channels and international markets. Moreover, we have begun manufacturing Hiya products in-house, a strategic shift that we expect will generate savings in the back half of 2026 as efficiencies scale and integration benefits materialize.

"Building on the strong momentum over the last several quarters, Rise Wellness is expected to accelerate net sales growth in 2026. Notably, Rise Wellness consists of two brands, Rise Bar and Protein Pop – a new product line we launched mid-year 2025. While Rise Bar sales were driven by entrance into a large club retailer in 2025, Protein Pop went from concept to launch on the shelves of a key retailer over a few short months. Much of the growth in Rise Wellness is expected to be driven by expansion of Protein Pop into the club retail channel."

------

The Company is providing its outlook for fiscal year 2026, as detailed in the table below:

---

| | |
|:---|:---|
| **Fiscal Year 2026 Outlook** | **Fiscal Year 2026 Outlook** |
| | **Range** |
| Core nutritional business net sales | $720 to $765 million\* |
| Hiya net sales | $140 to $155 million |
| Rise Wellness net sales | $65 to $80 million |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Consolidated net sales** | **$925 million to $1.0 billion** |
| Net earnings | $20.3 million to $26.6 million |
| Diluted EPS | $1.11 to $1.45 |
| Adjusted diluted EPS<sup>(1)</sup> | $1.95 to $2.29 |
| Adjusted EBITDA<sup>(2)</sup> | $101.3 million to $109.3 million |

---

*\*Reflects an expected favorable currency exchange rate impact of approximately $19 million, or 3% on net sales and one less week of operations compared to fiscal year 2025 which was a 53-week year.*

Doug Hekking, Chief Financial Officer, said, "Fourth-quarter and full-year net sales came in modestly ahead of our expectations, although reported GAAP results reflected the impact of two notable items. During the quarter, we recorded a non-cash impairment charge of $7.0 million of goodwill and intangibles in one of our reporting units, that resulted from a sustained decline in our share price and resulting market capitalization. We also incurred a $6.5 million charge related to our previously communicated cost realignment initiatives, primarily aligning headcount with sales levels. As a result of the impact of the impairment and cost realignment initiatives, the annualized effective income tax rate in the fourth quarter increased from 65.0% to 72.4%. The adjustment was approximately $3.1 million greater than what would have been expected using the previously expected 65.0% tax rate. The fourth quarter also included incremental net sales of approximately $11.2 million attributable to the additional week of operations in the core nutritional business.

"Looking ahead, we are projecting fiscal 2026 consolidated net sales in a range of flat to 8% growth. Our outlook for the core nutritional business anticipates an approximately 0-5% decline in fiscal 2026, but we remain confident that the actions underway will stabilize the business over time and ultimately position it to return to sustainable growth.

------

Hiya is anticipated to grow net sales 6% to 17%, while Rise Wellness is expected to continue to deliver accelerated net sales growth.

"We are making meaningful investments in inventory, working capital, and capital expenditures, while simultaneously deploying incremental operational resources to support the growth of Hiya and Rise Wellness including building brand awareness. These actions are designed to strengthen the scalability of both platforms and position the brands for sustained, long-term value creation."

_________________________

(1) Adjusted Diluted EPS is a non-GAAP financial measure. The Company excludes cost realignment expenses, impairment expense, gain on sale of assets, and acquisition-related costs, such as business transaction costs, integration expense and amortization expense from acquisition related intangible assets in calculating Adjusted Diluted EPS. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted EPS (Non-GAAP)" in this press release for an explanation and reconciliation of this non-GAAP financial measure.

(2) Adjusted EBITDA is a non-GAAP financial measure. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (Non-GAAP)" in this press release for an explanation and reconciliation of this non-GAAP financial measure.

**Non-GAAP Financial Measures** 

This press release contains the non-GAAP financial measures Adjusted EBITDA and Adjusted diluted EPS. Adjusted EBITDA is a Non-GAAP financial measure of earnings before interest, taxes, depreciation, and amortization that also excludes certain

------

adjustments as indicated below in the reconciliation from net earnings. Adjusted diluted EPS is a Non-GAAP financial measure of diluted earnings per share that excludes certain adjustments as indicated below in the reconciliation from diluted EPS.

Adjusted EBITDA (non-GAAP) is net earnings (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization, non-cash share-based compensation, transaction-related expenses and integration costs for the Hiya acquisition, cost realignment expenses, impairment expense, and gain on sale of assets. Adjusted EBITDA attributable to USANA (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to non-controlling interest related to Hiya.

Adjusted diluted EPS (non-GAAP) is diluted earnings (loss) per share (its most directly comparable GAAP financial measure) adjusted for amortization of intangible assets, transaction-related expenses, integration costs related to the Hiya acquisition, cost realignment expenses, impairment expense, and gain on sale of assets.

Management believes that Adjusted EBITDA (non-GAAP), Adjusted EBITDA attributable to USANA (non-GAAP), and Adjusted diluted EPS (non-GAAP), along with GAAP measures used by management, most appropriately reflect how the Company measures the business internally.

The Company prepares its financial statements using U.S. generally accepted accounting principles ("GAAP") and investors should not directly compare with or infer relationship from any of the Company's operating results presented in accordance with GAAP to Adjusted EBITDA and Adjusted diluted EPS. Non-GAAP financial measures have limitations in their usefulness to investors because they have no standardized meaning prescribed by GAAP and are not prepared under any comprehensive set of accounting rules or principles. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the

------

usefulness of non-GAAP financial information as a tool for comparison. As a result, the non-GAAP financial information is presented for supplemental informational purposes only and should not be considered in isolation from, or as a substitute for financial information presented in accordance with GAAP.

------

**Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (non-GAAP)**

**(in thousands)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Quarter Ended** | **Quarter Ended** | **Year Ended** | **Year Ended** |
| | **January 3, 2026** | **December 28, 2024** | **January 3, 2026** | **December 28, 2024** |
| **Net (loss) earnings attributable to USANA (GAAP)** | $**(1775)** | $**4454** | $**10760** | $**42030** |
| Net earnings attributable to noncontrolling interest | 180 | 30 | 717 | 30 |
| **Net (loss) earnings** | $**(1595)** | $**4484** | $**11477** | $**42060** |
| Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes | $5772 | $5945 | $30050 | $34291 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest (income) expense | (372) | (2609) | (1573) | (11038) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 5488 | 5590 | 21538 | 21935 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets - Hiya | 4798 | 294 | 18164 | 294 |
| **Earnings before interest, taxes, depreciation, and amortization (EBITDA)** | $**14091** | $**13704** | $**79656** | $**87542** |
| Add EBITDA adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash share-based compensation | 3750 | 3613 | 13828 | 14558 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction, integration and transition costs - Hiya | 443 | 8243 | 1314 | 8243 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory step-up - Hiya |  | 38 | 1126 | 38 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost realignment | 6463 |  | 6463 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment | 6967 |  | 6967 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on disposal of assets | (3240) |  | (3240) |  |
| **Consolidated adjusted EBITDA** | **28474** | **25598** | **106114** | **110381** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: Adjusted EBITDA attributable to noncontrolling interest | (1195) | (101) | (4799) | (101) |
| **Adjusted EBITDA attributable to USANA** | $**27279** | $**25497** | $**101315** | $**110280** |

---

------

**Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted Earnings Per Share (non-GAAP)**

**(in thousands, except per share data)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Quarter Ended** | **Quarter Ended** | **Year Ended** | **Year Ended** |
| | **January 3, 2026** | **December 28, 2024** | **January 3, 2026** | **December 28, 2024** |
| Net (loss) earnings attributable to USANA (GAAP) | $(1775) | $4454 | $10760 | $42030 |
| **(Loss) earnings per common share - Diluted (GAAP)** | $**(0.10)** | $**0.23** | $**0.58** | $**2.19** |
| Weighted Average common shares outstanding - Diluted | 18302 | 19104 | 18574 | 19162 |
| Adjustment to net (loss) earnings: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction, integration and transition costs - Hiya | $443 | $8243 | $1314 | $8243 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory step-up - Hiya |  | 38 | 1126 | 38 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost realignment | 6463 |  | 6463 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment | 6967 |  | 6967 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on disposal of assets | (3240) |  | (3240) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets - Hiya | 4798 | 294 | 18164 | 294 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to net (loss) earnings attributable to noncontrolling interest | (1015) | (70) | (4081) | (70) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax effect of adjustments to net earnings (loss) | (1658) | (823) | (1662) | (823) |
| Adjusted net earnings attributable to USANA | $10983 | $12136 | $35811 | $49712 |
| **Adjusted earnings per common share - Diluted** | $**0.60** | $**0.64** | $**1.93** | $**2.59** |
| Weighted average common shares outstanding - Diluted | 18302 | 19104 | 18574 | 19162 |

---

------

**Management Commentary Document and Conference Call**

For further information on the USANA's operating results, please see the Management Commentary document, which has been posted on the Company's website (http://ir.usana.com) under the Investor Relations section. USANA's management team will hold a conference call and webcast to discuss today's announcement with investors on Wednesday, February 18, 2026 at 11:00 AM Eastern Time. **Investors may listen to the call by accessing USANA's website at http://ir.usana.com**. The call will consist of brief opening remarks by the Company's management team, followed by a questions and answers session.

**Safe Harbor**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements are based on current plans, expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as "expect," "enhance," "drive," "anticipate," "intend," "improve," "promote," "should," "believe," "continue," "plan," "goal," "opportunity," "estimate," "predict," "may," "will," "could," and "would," and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding growth for Hiya and Rise Wellness in 2026 and continued growth in the future; statements about the Company's long-term growth; and the statements under the sub-heading "Fiscal Year 2026 Outlook." Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including: risks relating to global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Brand Partners; risk that our Brand Partner compensation plan, or changes that we make to the compensation plan, will not produce desired results, benefit our business or, in some cases, could harm our business; risk associated with

------

our launch of new products or reformulated existing products; risks related to Hiya's ability to adapt to changes in the digital marketing environment to continue to generate customer acquisition, including changes in social media advertising algorithms; risks related to Rise Wellness' dependence on product orders from certain key retailers – specifically, if future orders from those retailers do not meet our forecasts; risks related to governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets, including potential adverse impact from tariffs, trade policies or other international disputes by and among the United States, China, or other markets that are important to the Company; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with our operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; risk that Hiya and Rise Wellness disrupt our the Company's overall strategic plans and operations; the diversion of the attention of the management teams of USANA and Hiya from ongoing business operations; the ability to retain key personnel of Hiya and Rise Wellness; the ability to realize the benefits of the Hiya acquisition, including efficiencies and cost synergies; the ability to successfully integrate Hiya's business with USANA's business, at all or in a timely manner; and the amount of the costs, fees, expenses and charges related to the acquisition. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set

------

forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's expectations, except as required by law.

**About USANA** 

USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Brand Partners and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found at **www.usana.com**. USANA also owns a 78.8% controlling ownership stake in Hiya Health Products, a children's health and wellness company and a 100% interest in Rise Wellness. Hiya and Rise Wellness offer a variety of clean-label health products. More information on Hiya can be found at **www.hiyahealth.com**. More information on Rise Wellness can be found on **www.risebar.com**.

Investor contact: Andrew Masuda

Investor Relations

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(801) 954-7201

investor.relations@usanainc.com

Media contact: Sarah Searle

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(801) 954-7626

media@usanainc.com

------

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

**(in thousands, except per share data)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Quarter Ended** | **Quarter Ended** | **Year Ended** | **Year Ended** |
| | **January 3, 2026** | **December 28, 2024** | **January 3, 2026** | **December 28, 2024** |
| Net sales | $226200 | $213613 | $925257 | $854503 |
| Cost of sales | 49408 | 38553 | 200852 | 161212 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 176792 | 175060 | 724405 | 693291 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Brand Partner incentives | 81462 | 93502 | 336171 | 363699 |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 78081 | 73348 | 337372 | 263268 |
| &nbsp;&nbsp;&nbsp;Cost realignment and impairment | 13430 |  | 13430 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 172973 | 166850 | 686973 | 626967 |
| Earnings from operations | 3819 | 8210 | 37432 | 66324 |
| Other income (expense): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest income | 495 | 2738 | 2415 | 11319 |
| &nbsp;&nbsp;&nbsp;Interest expense | (123) | (129) | (842) | (281) |
| &nbsp;&nbsp;&nbsp;Other, net | (14) | (390) | 2522 | (1011) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income (expense), net | 358 | 2219 | 4095 | 10027 |
| Earnings before income taxes | 4177 | 10429 | 41527 | 76351 |
| Income taxes | 5772 | 5945 | 30050 | 34291 |
| &nbsp;&nbsp;&nbsp;Net (loss) earnings | (1595) | 4484 | 11477 | 42060 |
| Less: Net (loss) earnings attributable to redeemable noncontrolling interest | (180) | (30) | (717) | (30) |
| &nbsp;&nbsp;&nbsp;Net (loss) earnings attributable to USANA | $(1775) | $4454 | $10760 | $42030 |
| (Loss) earnings per common share attributable to USANA |  |  |  |  |
| (Loss) earnings per share - diluted | $(0.10) | $0.23 | $0.58 | $2.19 |
| Weighted average shares outstanding - diluted | 18302 | 19104 | 18574 | 19162 |

---

------

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(in thousands)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **As of<br>January 3,<br>2026** | **As of<br>December 28,<br>2024** |
| **ASSETS** | | |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $158380 | $181768 |
| &nbsp;&nbsp;&nbsp;Inventories | 102608 | 69735 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 27417 | 27684 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 288405 | 279187 |
| Property and equipment, net | 94383 | 94565 |
| Goodwill | 137962 | 144168 |
| Intangible assets, net | 133151 | 151823 |
| Deferred tax assets | 27209 | 19644 |
| Other assets\* | 61805 | 58806 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $742915 | $748193 |
| **LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST, AND STOCKHOLDERS' EQUITY** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $17263 | $11984 |
| &nbsp;&nbsp;&nbsp;Line of credit | 14000 | 23000 |
| &nbsp;&nbsp;&nbsp;Other current liabilities | 97302 | 104641 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 128565 | 139625 |
| Deferred tax liabilities | 4892 | 4073 |
| Other long-term liabilities | 23186 | 18163 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 156643 | 161861 |
| Redeemable noncontrolling interest | 53168 | 54223 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity attributable to USANA | 533104 | 532109 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities, redeemable noncontrolling interest, and stockholders' equity** | $742915 | $748193 |

---

\*Includes noncurrent inventories of $4,799 and $2,688 as of 03-Jan-26 and 28-Dec-24, respectively. Total inventories were $107,407 and $72,423 as of 03-Jan-26 and 28-Dec-24, respectively.

------

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**SALES BY REGION**

**(in thousands)**

**(unaudited)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | | | | |
| | **January 3,<br>2026** | **January 3,<br>2026** | **December 28,<br>2024** | **December 28,<br>2024** |<br>**Change from prior<br>year** |<br>**Percent change** |<br>**Currency impact on<br>sales** |<br>**Percent change<br>excluding currency<br>impact** |
| Core nutritional: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Asia Pacific |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Greater China | $100053 | 44.2% | $112587 | 52.7% | $(12534) | (11.1)% | $1332 | (12.3)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Southeast Asia Pacific | 34211 | 15.1% | 38061 | 17.8% | (3850) | (10.1)% | 592 | (11.7)% |
| &nbsp;&nbsp;&nbsp;&nbsp;North Asia | 16830 | 7.5% | 16542 | 7.8% | 288 | 1.7% | (614) | 5.5% |
| &nbsp;&nbsp;Asia Pacific total | 151094 | 66.8% | 167190 | 78.3% | (16096) | (9.6)% | 1310 | (10.4)% |
| &nbsp;&nbsp;Americas and Europe | 40494 | 17.9% | 42776 | 20.0% | (2282) | (5.3)% | 619 | (6.8)% |
| Core nutritional total | 191588 | 84.7% | 209966 | 98.3% | (18378) | (8.8)% | 1929 | (9.7)% |
| Hiya<sup>(1)</sup> | 30105 | 13.3% | 1970 | 0.9% | 28135 | N/A |  | N/A |
| Other | 4507 | 2.0% | 1677 | 0.8% | 2830 | 168.8% |  | 168.8% |
| Consolidated total | $226200 | 100.0% | $213613 | 100.0% | $12587 | 5.9% | $1929 | 5.0% |

---

______________________________

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup>Percentage change for Hiya is not applicable due to timing of the acquisition.

------

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**CORE NUTRITIONAL BUSINESS ACTIVE BRAND PARTNERS AND ACTIVE PREFERRED CUSTOMERS BY REGION**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Core Nutritional Business Active Brand Partners by Region**<sup>(1)</sup> | **Core Nutritional Business Active Brand Partners by Region**<sup>(1)</sup> | **Core Nutritional Business Active Brand Partners by Region**<sup>(1)</sup> | **Core Nutritional Business Active Brand Partners by Region**<sup>(1)</sup> | **Core Nutritional Business Active Brand Partners by Region**<sup>(1)</sup> |
| | **As of <br>January 3, 2026** | **As of <br>January 3, 2026** | **As of <br>December 28, 2024** | **As of <br>December 28, 2024** |
| Asia Pacific |  |  |  |  |
| &nbsp;&nbsp;Greater China | 61000 | 35.1% | 67000 | 35.4% |
| &nbsp;&nbsp;Southeast Asia Pacific | 46000 | 26.4% | 51000 | 27.0% |
| &nbsp;&nbsp;North Asia | 27000 | 15.5% | 26000 | 13.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Asia Pacific Total | 134000 | 77.0% | 144000 | 76.2% |
| Americas and Europe | 40000 | 23.0% | 45000 | 23.8% |
|  | 174000 | 100.0% | 189000 | 100.0% |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Core Nutritional Business Active Preferred Customers by Region**<sup>(2)</sup> | **Core Nutritional Business Active Preferred Customers by Region**<sup>(2)</sup> | **Core Nutritional Business Active Preferred Customers by Region**<sup>(2)</sup> | **Core Nutritional Business Active Preferred Customers by Region**<sup>(2)</sup> | **Core Nutritional Business Active Preferred Customers by Region**<sup>(2)</sup> |
| | **As of <br>January 3, 2026** | **As of <br>January 3, 2026** | **As of <br>December 28, 2024** | **As of <br>December 28, 2024** |
| Asia Pacific |  |  |  |  |
| &nbsp;&nbsp;Greater China | 147000 | 69.0% | 179000 | 67.6% |
| &nbsp;&nbsp;Southeast Asia Pacific | 17000 | 8.0% | 26000 | 9.8% |
| &nbsp;&nbsp;North Asia | 8000 | 3.8% | 12000 | 4.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;Asia Pacific Total | 172000 | 80.8% | 217000 | 81.9% |
| Americas and Europe | 41000 | 19.2% | 48000 | 18.1% |
|  | 213000 | 100.0% | 265000 | 100.0% |

---

**______________________________**

<sup>(1)</sup> Brand Partners are independent distributors of our products who also purchase our products for their personal use. We only count as active those Brand Partners who have purchased from us any time during the most recent three-month period, either for personal use or resale.

<sup>(2)</sup> Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

------

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**OPERATING RESULTS AS A PERCENTAGE OF NET SALES**

**(unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** |
| | **January 3, 2026** | **January 3, 2026** | **January 3, 2026** | **December 28, 2024** | **December 28, 2024** | **December 28, 2024** |
| | **Core nutritional & other** | **Hiya direct-to-consumer** | **Consolidated** | **Core nutritional & other** | **Hiya direct-to-consumer** | **Consolidated** |
| Net sales | 100.0% | 100.0% | **100.0%** | 100.0% | 100.0% | **100.0%** |
| Cost of sales | 20.6% | 29.9% | **21.8%** | 17.9% | 30.4% | **18.0%** |
| &nbsp;&nbsp;&nbsp;Gross profit | 79.4% | 70.1% | **78.2%** | 82.1% | 69.6% | **82.0%** |
| Operating expenses: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Brand Partner incentives | 41.5% | —% | **36.0%** | 44.2% | —% | **43.8%** |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 29.5% | 67.2% | **34.5%** | 34.1% | 62.2% | **34.3%** |
| &nbsp;&nbsp;Cost realignment and impairment | 6.8% | —% | **5.9%** | —% | —% | **—%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 77.8% | 67.2% | **76.4%** | 78.3% | 62.2% | **78.1%** |
| Earnings from operations | 1.6% | 2.9% | **1.8%** | 3.8% | 7.4% | **3.9%** |
| Amortization of acquired intangible assets | 0.1% | 15.9% | **2.3%** | 0.1% | 14.9% | **0.2%** |
|  | **Year Ended** | **Year Ended** | **Year Ended** | **Year Ended** | **Year Ended** | **Year Ended** |
|  | **January 3, 2026** | **January 3, 2026** | **January 3, 2026** | **December 28, 2024** | **December 28, 2024** | **December 28, 2024** |
|  | **Core nutritional & other** | **Hiya direct-to-consumer** | **Consolidated** | **Core nutritional & other** | **Hiya direct-to-consumer** | **Consolidated** |
| Net sales | 100.0% | 100.0% | **100.0%** | 100.0% | 100.0% | **100.0%** |
| Cost of sales | 19.5% | 35.1% | **21.7%** | 18.8% | 30.4% | **18.9%** |
| &nbsp;&nbsp;Gross profit | 80.5% | 64.9% | **78.3%** | 81.2% | 69.6% | **81.1%** |
| Operating expenses: |  |  |  |  |  |  |
| &nbsp;&nbsp;Brand Partner incentives | 42.4% | —% | **36.3%** | 42.7% | —% | **42.6%** |
| &nbsp;&nbsp;Selling, general and administrative | 32.2% | 62.3% | **36.5%** | 30.7% | 62.2% | **30.8%** |
| &nbsp;&nbsp;Cost realignment and impairment | 1.7% | —% | **1.5%** | —% | —% | **—%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 76.3% | 62.3% | **74.3%** | 73.4% | 62.2% | **73.4%** |
| Earnings from operations | 4.2% | 2.6% | **4.0%** | 7.8% | 7.4% | **7.7%** |
| Amortization of acquired intangible assets | 0.2% | 13.8% | **2.1%** | 0.1% | 14.9% | **0.2%** |

---

## Exhibit 99.2

![usanacorplogoresized.jpg](usanacorplogoresized.jpg)

**USANA Health Sciences, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; February 17, 2026**

***Q4 2025 Management Commentary***

**Key Financial and Operating Results**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Q4 2025** | **Q4 2024** | **FY 2025** | **FY 2024** |
| Net sales | $226.2 | $213.6 | $925.3 | $854.5 |
| Net (loss) earnings\* | $-1.8 | $4.5 | $10.8 | $42.0 |
| Diluted EPS | $-0.10 | $0.23 | $0.58 | $2.19 |
| Adjusted diluted EPS<sup>(1)</sup> | $0.60 | $0.64 | $1.93 | $2.59 |
| Adjusted EBITDA<sup>(2)</sup> | $27.3 | $25.5 | $101.3 | $110.3 |
| USANA Active Customers | 387000 | 454000 | 387000 | 454000 |
| Hiya Active Monthly Subscribers | 181700 | N/A | 181700 | N/A |

---

*\*Pretax earnings for Q4 2025 totaled $4.0 million with income tax expense of $5.8 million. The adjustment to income taxes during the period, largely as a result of one-time impairment and cost realignment charges, is about $3.1 million greater than what would have been expected using the previously expected 65% tax rate.*

*Net sales, Net (loss) earnings and Adjusted EBITDA figures in millions.*

*Net earnings, EPS and Adjusted EBITDA figures represent amounts attributable to USANA.*

**Fiscal Year 2026 Outlook**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consolidated net sales between $925 million and $1.0 billion, or flat to 8% growth.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net earnings between $20.3 million and $26.6 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Diluted EPS between $1.11 and $1.45.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted Diluted EPS<sup>(1)</sup> between $1.95 and $2.29.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA<sup>(2)</sup> between $101.3 million and $109.3 million.

**Overview**

We reported fourth quarter net sales in line with the preliminary results we announced on January 12th. Net sales in our core nutritional business increased sequentially, led by growth in key markets including mainland China, the United States and Canada, reflecting signs of stabilization in active customer counts. Hiya, our direct-to-consumer

------

(DTC) business, experienced sequential sales and Active Monthly Subscriber trends consistent with our expectations, reflecting normal fourth quarter seasonality.

Rise Wellness, which consists of two brands (Rise Bar and Protein Pop), delivered another quarter of strong top line growth, with fourth quarter net sales more than tripling year-over-year, driven by solid order activity with key retail partners.

Consolidated net earnings in the fourth quarter were negatively impacted by two one-time items: 1) a non-cash impairment charge of $7.0 million of goodwill and intangibles in one of our reporting units that resulted from a sustained decline in our share price and resulting market capitalization, and 2) a $6.5 million charge related to our previously communicated cost realignment initiatives in our core nutritional business, which was primarily focused on aligning headcount with sales levels. These two items were partially offset by a $3.2 million gain on sale of assets. On a non-GAAP basis, fourth quarter adjusted EBITDA and adjusted diluted EPS came in modestly ahead of our expectations.

Fiscal 2025 net sales grew 8%, reflecting the full-year contribution from Hiya and robust growth at Rise Wellness, partially offset by a decline in our core nutritional business.

Despite operating in an environment of year-over-year declines, our core nutritional business continued to execute against its commercial strategy and delivered meaningful progress in several areas. We advanced the rollout of our enhanced Brand Partner compensation plan, further strengthening the competitiveness and appeal of USANA's business opportunity in today's fast-moving economy. We also accelerated product innovation by shortening development timelines for new and upgraded products, ensuring a more robust and relevant pipeline. Additionally, we aligned our cost structure to become more agile with a disciplined focus on profitable growth. Collectively, we

------

believe these actions will position the core nutritional business for improved operational leverage and support a return to sustainable future growth.

Hiya delivered solid year-over-year top-line growth each quarter and delivered 17% net sales growth in fiscal 2025. The business successfully expanded its product portfolio while also launching special-edition Disney-branded multivitamin packs to broaden consumer appeal. Operationally, the USANA and Hiya teams executed key integration milestones to drive operational efficiencies, including the implementation of a new ERP system, transitioning to a new logistics partner, and transferring the majority of 3rd party production to USANA's in-house manufacturing facility. Hiya also advanced strategic groundwork for entry into new channels and international markets, positioning the company for another year of double-digit net sales growth in fiscal 2026.

Rise Wellness' net sales in fiscal 2025 tripled, as it experienced significant growth by successfully expanding with key retail partners. The company is projected to deliver a robust year of net sales growth in fiscal 2026, largely driven by the launch of Protein Pop into retail and club retail channels.

Overall, we continued to execute our omnichannel diversification strategy to drive long-term growth beyond our core nutritional business as well as restructure and modernize our business model for today's evolving marketplace. Net sales outside of our core nutritional business represented 16% of consolidated net sales in 2025, up from 1% in 2024. We expect this share to increase to more than 20% of consolidated net sales in fiscal 2026, driven by strong growth in Hiya and significant growth in Rise Wellness.

------

**Q4 2025 Financial Performance**

---

| | | | |
|:---|:---|:---|:---|
| **Consolidated Results** | **Consolidated Results** | **Consolidated Results** | **Consolidated Results** |
| | | **Year-Over-Year** | **Sequentially** |
| **Net sales** | $226 million | +6% \* | +6% \* |
| **Net (loss)** | -$1.8 million | N/A | N/A |
| **Diluted EPS** | -$0.10 | N/A | N/A |
| **Adjusted diluted EPS**<sup>(1)</sup> | $0.60 | -6% | N/A |
| **Adjusted EBITDA**<sup>(2)</sup> | $27.0 million | +7% | +98% |

---

*\*No meaningful FX impact*

*Net (loss) earnings, EPS and Adjusted EBITDA figures represent amounts attributable to USANA*

**Fiscal Year 2025 Financial Performance**

---

| | | |
|:---|:---|:---|
| **Consolidated Results** | **Consolidated Results** | **Consolidated Results** |
| **Net sales** | $925 million | +8% YOY |
|  |  | +9% constant currency |
|  |  | -$3 million YOY FX impact |
| **Net earnings** | $10.8 million | -74% |
| **Diluted EPS** | $0.58 | -74% |
| **Adjusted diluted EPS**<sup>(1)</sup> | $1.93 | -25% |
| **Adjusted EBITDA**<sup>(2)</sup> | $101.3 million | -8% |

---

*Net earnings, EPS and Adjusted EBITDA figures represent amounts attributable to USANA*

**Balance Sheet**

We ended the year with $158 million in cash and cash equivalents and $14 million of debt. As of January 3, 2026, inventory totaled $107 million, an increase of approximately $35 million, or 48% compared to balances at year-end 2024. This increase was primarily driven by the addition of inventory to support the rapid growth of the Rise Wellness brands and a planned ramp up of raw materials inventory as part of bringing the production of Hiya products in-house. Importantly, our balance sheet remains in a strong net cash position, providing the financial flexibility to continue executing our strategic priorities.

We repurchased 927,000 shares in fiscal 2025 for an investment of $28 million. As of January 3, 2026, we had approximately $34 million remaining under the current share repurchase authorization.

------

**Quarterly Income Statement Discussion**

<u>Gross margin decreased 380 basis points from the prior year to 78.2% of net sales.</u> The decrease is largely attributed to an approximate 265 basis point unfavorable impact on consolidated results from the inclusion of Hiya and Rise Wellness, which carries lower gross margins relative to the core nutritional business. Gross margin in the core nutritional business declined 115 basis points from the prior year, driven primarily by higher costs in the current year quarter.

<u>Brand Partner Incentives decreased 780 basis points from the prior year to 36.0% of net sales on a consolidated basis.</u> The decrease is largely attributable to an approximate 575 basis point impact on consolidated results from Hiya and Rise Wellness, which do not payout Brand Partner Incentives. For the core nutritional business, Brand Partner Incentives decreased 205 basis points year-over-year, which was driven by lower accruals for incentive trips and promotions as well as a favorable shift in market mix.

<u>Selling, General and Administrative expenses increased 20 basis points from the prior year to 34.5% as a percentage of net sales.</u> The change in SG&A expenses for the quarter was driven by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Higher operating costs attributable to Hiya and Rise Wellness including increased advertising costs, the amortization of purchased intangibles, and infrastructure costs to support growth initiatives that collectively represented a 370 basis point increase in consolidated SG&A; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A decrease in costs incurred by the core nutritional business including the absence of costs related to the acquisition of Hiya, a gain on the sale of an asset, and a decrease in event and costs to support Brand Partners that collectively represented a 350 basis point decrease in consolidated SG&A.

<u>Cost Realignment and Impairment.</u> During the quarter, we recorded a non-cash impairment charge of $7.0 million of goodwill and intangibles in one of our reporting units, that resulted from a sustained decline in our share price and resulting market

------

capitalization. Additionally, we also incurred a $6.5 million charge related to our previously communicated cost realignment initiatives, which focused on aligning headcount with sales performance.

<u>The year-to-date effective tax rate increased to 72.4% from the 44.9% reported in fiscal 2024.</u> The higher effective tax rate was driven, in great part, by challenges in aligning revenue generated and cost incurred geographically, recognition of impairment charges, and costs incurred related to our cost realignment initiatives.

**Q4 2025 Core Nutritional Business Regional Results:**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Asia Pacific Region** | **Asia Pacific Region** | **Asia Pacific Region** | **Asia Pacific Region** | **Asia Pacific Region** |
| | | **Year-Over-Year** | **Year-over-Year (Constant Currency)** | **Sequentially** |
| **Net sales** | $151 million | -10% | No material FX impact | +8% |
| **USANA Active Customers** | 306000 | -15% | N/A | -1% |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** |
| | | | **Year-Over-Year** | **Year-over-Year (Constant Currency)** | **Sequentially** |
| **Greater China** | **Net sales** | $100 million | -11% | No material FX impact | +8% |
| **Greater China** | **USANA Active** | 208000 | -15% | N/A | -1% |
| **Greater China** | **Customers** | 208000 | -15% | N/A | -1% |
| **North Asia** | **Net sales** | $17 million | +2% | +5% | -5% |
| **North Asia** | **USANA Active** | 35000 | -8% | N/A | -5% |
| **North Asia** | **Customers** | 35000 | -8% | N/A | -5% |
| **Southeast Asia Pacific** | **Net sales** | $34 million | -10% | -12% | +17% |
| **Southeast Asia Pacific** | **USANA Active** | 63000 | -18% | N/A | +3% |
| **Southeast Asia Pacific** | **Customers** | 63000 | -18% | N/A | +3% |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Americas and Europe Region** | **Americas and Europe Region** | **Americas and Europe Region** | **Americas and Europe Region** | **Americas and Europe Region** |
| | | **Year-Over-Year** | **Year-over-Year (Constant Currency)** | **Sequentially** |
| **Net sales\*** | $45 million | +1% | Flat | +4% |
| **USANA Active Customers** | 81000 | -13% | N/A | +1% |

---

*\*Includes $4.5 million of 'Other'*

Sequential performance in the fourth quarter was driven by a modest pickup in sales activity and leader productivity along with the additional week of operations. The year-over-year decline in net sales results and Active Customers reflects lower Brand Partner productivity.

**Q4 2025 Hiya Direct-to-Consumer Results:**

---

| | |
|:---|:---|
| **Hiya** | **Hiya** |
| **Net sales** | $30 million |
| **Active Monthly Subscribers** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;181700 |

---

Fourth quarter results met our expectations with net sales and Active Monthly Subscribers down modestly on a sequential basis, reflecting normal seasonality in what is typically a lighter quarter for customer acquisition.

------

**Fiscal Year 2026 Outlook**

The Company is providing its outlook for fiscal year 2026, as follows:

---

| | |
|:---|:---|
| **Fiscal Year 2026 Outlook** | **Fiscal Year 2026 Outlook** |
| | **Range** |
| Core nutritional business net sales | $720 to $765 million\* |
| Hiya net sales | $140 to $155 million |
| Rise Wellness net sales | $65 to $80 million |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Consolidated net sales** | **$925 million to $1.0 billion** |
| Net earnings | $20.3 million to $26.6 million |
| Diluted EPS | $1.11 to $1.45 |
| Adjusted diluted EPS<sup>(1)</sup> | $1.95 to $2.29 |
| Adjusted EBITDA<sup>(2)</sup> | $101.3 million to $109.3 million |
| Consolidated effective tax rate | 60% to 55% |
| Diluted share count | Approximately 18.3 million |

---

*\*Reflects an expected favorable currency exchange rate impact of approximately $19 million, or 3% on net sales and one less week of operations compared to fiscal year 2025 which was a 53-week year.*

We are projecting fiscal 2026 consolidated net sales in a range of flat to 8% growth. Our outlook for the core nutritional business anticipates an approximately flat to 5% decline in fiscal 2026, but we remain confident that the actions underway will stabilize the business over time and ultimately position it to return to sustainable growth. Hiya is anticipated to grow net sales 6% to 17%. Rise Wellness is expected to continue to deliver accelerated net sales growth of 300% to 390% and operate at roughly breakeven in fiscal 2026 as we continue to invest in future growth opportunities.

We are making meaningful investments across inventory, working capital, and capital expenditures, while deploying incremental operational resources to support the growth of Hiya and Rise Wellness and to build brand awareness. These actions are designed to strengthen the scalability of both platforms and position the brands for sustained, long-term value creation.

------

**2026 Operating Strategy**

We are leveraging our strong foundation in the nutrition business and expanding beyond our legacy channel to connect with a greater number of health-conscious consumers worldwide. We see an extraordinary opportunity in a growing global health and wellness market to strengthen our brand relevance through an omnichannel approach. By deepening consumer engagement, empowering our Brand Partners, and executing with discipline, we believe we can accelerate profitable growth, extend our competitive advantages, and deliver sustainable long-term value for our shareholders.

We also remain focused on product innovation and development to meet the evolving nutritional needs of our consumers. We introduced several new products and upgraded several top-selling products in 2025, and plan to launch these products across all markets in 2026. Furthermore, we intend to accelerate our technology initiatives to modernize our core systems and fundamentally improve how customers experience our brand while driving future cost efficiencies across our IT infrastructure. We are planning to strategically leverage best-in-class third-party platforms to move faster, and scale smarter. Our focus is on deploying the most effective technologies and partnering with industry-leading providers to create real value for customers and a durable advantage for our business. This plan is still being finalized and is not reflected in our fiscal 2026 guidance, and we will provide an update upon its full formalization and approval.

Hiya is expected to deliver solid top line growth in 2026, driven by continued strength in its core DTC business and early expansion into new distribution channels and international markets. For example, Hiya launched in Canada in January and will launch in the U.K. in March. Additionally, the company's products will soon be available at a large retailer beginning in April. Moreover, we are leveraging USANA assets and expertise to support margin expansion. We have begun manufacturing Hiya products in-house, a strategic shift that we expect will generate savings in the back half of 2026 as efficiencies scale and integration benefits materialize.

------

Building on the strong momentum over the last several quarters, Rise Wellness is expected to accelerate net sales growth in 2026. Notably, Rise Wellness consists of two brands, Rise Bar and Protein Pop – a new product line we launched mid-year 2025. While Rise Bar sales were driven by entrance into a large club retailer in 2025, Protein Pop went from concept to launch on the shelves of a key retailer over a few short months. Much of the growth in Rise Wellness is expected to be driven by expansion of Protein Pop into Costco and with other large retail partners.

In closing, we are actively repositioning our core nutritional business for long-term growth and remain confident in the actions we are taking to stabilize its performance over time. At the same time, our portfolio of high-growth consumer brands, supported by a strong balance sheet, positions us to diversify our revenue streams and build an omnichannel enterprise. While important work remains, we are executing with focus and investing in the capabilities needed to modernize the business and strengthen our long-term competitiveness.

**Kevin Guest**

Chairman and CEO

**Douglas Hekking**

CFO

------

_________________________

(1) Adjusted Diluted EPS is a non-GAAP financial measure. The Company excludes cost realignment expenses, impairment expense, gain on sale of assets, and acquisition-related costs, such as business transaction costs, integration expense and amortization expense from acquisition related intangible assets in calculating Adjusted Diluted EPS. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted EPS (Non-GAAP)" in this Management Commentary for an explanation and reconciliation of this non-GAAP financial measure.

(2) Adjusted EBITDA is a non-GAAP financial measure. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (Non-GAAP)" in this Management Commentary for an explanation and reconciliation of this non-GAAP financial measure.

**Non-GAAP Financial Measures** 

This Management Commentary contains the non-GAAP financial measures Adjusted EBITDA and Adjusted diluted EPS. Adjusted EBITDA is a Non-GAAP financial measure of earnings before interest, taxes, depreciation, and amortization that also excludes certain adjustments as indicated below in the reconciliation from net earnings. Adjusted diluted EPS is a Non-GAAP financial measure of diluted earnings per share that excludes certain adjustments as indicated below in the reconciliation from diluted EPS.

Adjusted EBITDA (non-GAAP) is net earnings (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization, non-cash share-based compensation, transaction-related expenses and integration costs for the Hiya acquisition, cost realignment expenses, impairment expense, and gain on sale of assets. Adjusted EBITDA

------

attributable to USANA (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to non-controlling interest related to Hiya.

Adjusted diluted EPS (non-GAAP) is diluted earnings (loss) per share (its most directly comparable GAAP financial measure) adjusted for amortization of intangible assets, transaction-related expenses, integration costs related to the Hiya acquisition, cost realignment expenses, impairment expense, and gain on sale of assets.

Management believes that Adjusted EBITDA (non-GAAP), Adjusted EBITDA attributable to USANA (non-GAAP), and Adjusted diluted EPS (non-GAAP), along with GAAP measures used by management, most appropriately reflect how the Company measures the business internally.

The Company prepares its financial statements using U.S. generally accepted accounting principles ("GAAP") and investors should not directly compare with or infer relationship from any of the Company's operating results presented in accordance with GAAP to Adjusted EBITDA and Adjusted diluted EPS. Non-GAAP financial measures have limitations in their usefulness to investors because they have no standardized meaning prescribed by GAAP and are not prepared under any comprehensive set of accounting rules or principles. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of non-GAAP financial information as a tool for comparison. As a result, the non-GAAP financial information is presented for supplemental informational purposes only and should not be considered in isolation from, or as a substitute for financial information presented in accordance with GAAP.

------

**Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (non-GAAP)**

**(in thousands)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Quarter Ended** | **Quarter Ended** | **Year Ended** | **Year Ended** |
| | **January 3, 2026** | **December 28, 2024** | **January 3, 2026** | **December 28, 2024** |
| **Net (loss) earnings attributable to USANA (GAAP)** | $**(1775)** | $**4454** | $**10760** | $**42030** |
| Net earnings attributable to noncontrolling interest | 180 | 30 | 717 | 30 |
| **Net (loss) earnings** | $**(1595)** | $**4484** | $**11477** | $**42060** |
| Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes | $5772 | $5945 | $30050 | $34291 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest (income) expense | (372) | (2609) | (1573) | (11038) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 5488 | 5590 | 21538 | 21935 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets - Hiya | 4798 | 294 | 18164 | 294 |
| **Earnings before interest, taxes, depreciation, and amortization (EBITDA)** | $**14091** | $**13704** | $**79656** | $**87542** |
| Add EBITDA adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash share-based compensation | 3750 | 3613 | 13828 | 14558 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction, integration and transition costs - Hiya | 443 | 8243 | 1314 | 8243 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory step-up - Hiya |  | 38 | 1126 | 38 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost realignment | 6463 |  | 6463 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment | 6967 |  | 6967 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on disposal of assets | (3240) |  | (3240) |  |
| **Consolidated adjusted EBITDA** | **28474** | **25598** | **106114** | **110381** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: Adjusted EBITDA attributable to noncontrolling interest | (1195) | (101) | (4799) | (101) |
| **Adjusted EBITDA attributable to USANA** | $**27279** | $**25497** | $**101315** | $**110280** |

---

------

**Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted Earnings Per Share (non-GAAP)**

**(in thousands, except per share data)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Quarter Ended** | **Quarter Ended** | **Year Ended** | **Year Ended** |
| | **January 3, 2026** | **December 28, 2024** | **January 3, 2026** | **December 28, 2024** |
| Net (loss) earnings attributable to USANA (GAAP) | $(1775) | $4454 | $10760 | $42030 |
| **(Loss) earnings per common share - Diluted (GAAP)** | $**(0.10)** | $**0.23** | $**0.58** | $**2.19** |
| Weighted Average common shares outstanding - Diluted | 18302 | 19104 | 18574 | 19162 |
| Adjustment to net (loss) earnings: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction, integration and transition costs - Hiya | $443 | $8243 | $1314 | $8243 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory step-up - Hiya |  | 38 | 1126 | 38 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost realignment | 6463 |  | 6463 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment | 6967 |  | 6967 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on disposal of assets | (3240) |  | (3240) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets - Hiya | 4798 | 294 | 18164 | 294 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to net (loss) earnings attributable to noncontrolling interest | (1015) | (70) | (4081) | (70) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax effect of adjustments to net earnings (loss) | (1658) | (823) | (1662) | (823) |
| Adjusted net earnings attributable to USANA | $10983 | $12136 | $35811 | $49712 |
| **Adjusted earnings per common share - Diluted** | $**0.60** | $**0.64** | $**1.93** | $**2.59** |
| Weighted average common shares outstanding - Diluted | 18302 | 19104 | 18574 | 19162 |

---

------

**Operating Results as a Percentage of Net Sales**

**(unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** |
| | **January 3, 2026** | **January 3, 2026** | **January 3, 2026** | **December 28, 2024** | **December 28, 2024** | **December 28, 2024** |
| | **Core nutritional & other** | **Hiya direct-to-consumer** | **Consolidated** | **Core nutritional & other** | **Hiya direct-to-consumer** | **Consolidated** |
| Net sales | 100.0% | 100.0% | **100.0%** | 100.0% | 100.0% | **100.0%** |
| Cost of sales | 20.6% | 29.9% | **21.8%** | 17.9% | 30.4% | **18.0%** |
| &nbsp;&nbsp;&nbsp;Gross profit | 79.4% | 70.1% | **78.2%** | 82.1% | 69.6% | **82.0%** |
| Operating expenses: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Brand Partner incentives | 41.5% | —% | **36.0%** | 44.2% | —% | **43.8%** |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 29.5% | 67.2% | **34.5%** | 34.1% | 62.2% | **34.3%** |
| &nbsp;&nbsp;Cost realignment and impairment | 6.8% | —% | **5.9%** | —% | —% | **—%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 77.8% | 67.2% | **76.4%** | 78.3% | 62.2% | **78.1%** |
| Earnings from operations | 1.6% | 2.9% | **1.8%** | 3.8% | 7.4% | **3.9%** |
| Amortization of acquired intangible assets | 0.1% | 15.9% | **2.3%** | 0.1% | 14.9% | **0.2%** |
|  | **Year Ended** | **Year Ended** | **Year Ended** | **Year Ended** | **Year Ended** | **Year Ended** |
|  | **January 3, 2026** | **January 3, 2026** | **January 3, 2026** | **December 28, 2024** | **December 28, 2024** | **December 28, 2024** |
|  | **Core nutritional & other** | **Hiya direct-to-consumer** | **Consolidated** | **Core nutritional & other** | **Hiya direct-to-consumer** | **Consolidated** |
| Net sales | 100.0% | 100.0% | **100.0%** | 100.0% | 100.0% | **100.0%** |
| Cost of sales | 19.5% | 35.1% | **21.7%** | 18.8% | 30.4% | **18.9%** |
| &nbsp;&nbsp;Gross profit | 80.5% | 64.9% | **78.3%** | 81.2% | 69.6% | **81.1%** |
| Operating expenses: |  |  |  |  |  |  |
| &nbsp;&nbsp;Brand Partner incentives | 42.4% | —% | **36.3%** | 42.7% | —% | **42.6%** |
| &nbsp;&nbsp;Selling, general and administrative | 32.2% | 62.3% | **36.5%** | 30.7% | 62.2% | **30.8%** |
| &nbsp;&nbsp;Cost realignment and impairment | 1.7% | —% | **1.5%** | —% | —% | **—%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 76.3% | 62.3% | **74.3%** | 73.4% | 62.2% | **73.4%** |
| Earnings from operations | 4.2% | 2.6% | **4.0%** | 7.8% | 7.4% | **7.7%** |
| Amortization of acquired intangible assets | 0.2% | 13.8% | **2.1%** | 0.1% | 14.9% | **0.2%** |

---

------

**Management Commentary Document and Conference Call**

For further information on the USANA's operating results, please see the Management Commentary document, which has been posted on the Company's website (http://ir.usana.com) under the Investor Relations section. USANA's management team will hold a conference call and webcast to discuss today's announcement with investors on Wednesday, February 18, 2026 at 11:00 AM Eastern Time. **Investors may listen to the call by accessing USANA's website at http://ir.usana.com**. The call will consist of brief opening remarks by the Company's management team, followed by a questions and answers session.

**Safe Harbor**

This Management Commentary contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements are based on current plans, expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as "expect," "enhance," "drive," "anticipate," "intend," "improve," "promote," "should," "believe," "continue," "plan," "goal," "opportunity," "estimate," "predict," "may," "will," "could," and "would," and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding growth for Hiya and Rise Wellness in 2026 and continued growth in the future; statements about the Company's long-term growth; and the statements under the sub-heading "Fiscal Year 2026 Outlook." Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including: risks relating to global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Brand Partners; risk that our Brand Partner compensation plan, or changes that we make to the compensation plan, will not produce desired results, benefit our business or, in some cases, could harm our business; risk associated with

------

our launch of new products or reformulated existing products; risks related to Hiya's ability to adapt to changes in the digital marketing environment to continue to generate customer acquisition, including changes in social media advertising algorithms; risks related to Rise Wellness' dependence on product orders from certain key retailers – specifically, if future orders from those retailers do not meet our forecasts; risks related to governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets, including potential adverse impact from tariffs, trade policies or other international disputes by and among the United States, China, or other markets that are important to the Company; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with our operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; risk that Hiya and Rise Wellness disrupt our the Company's overall strategic plans and operations; the diversion of the attention of the management teams of USANA and Hiya from ongoing business operations; the ability to retain key personnel of Hiya and Rise Wellness; the ability to realize the benefits of the Hiya acquisition, including efficiencies and cost synergies; the ability to successfully integrate Hiya's business with USANA's business, at all or in a timely manner; and the amount of the costs, fees, expenses and charges related to the acquisition. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this Management

------

Commentary set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's expectations, except as required by law.

**About USANA**

USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Brand Partners and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found at **www.usana.com.** USANA also owns a 78.8% controlling ownership stake in Hiya Health Products, a children's health and wellness company and a 100% interest in Rise Wellness. Hiya and Rise Wellness offer a variety of clean-label health products. More information on Hiya can be found at **www.hiyahealth.com**. More information on Rise Wellness can be found on **www.risebar.com.**

Investor contact: Andrew Masuda

Investor Relations

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(801) 954-7201

investor.relations@usanainc.com

Media contact: Sarah Searle

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(801) 954-7626

media@usanainc.com

<br>